Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Jul 2;12(7):1766.
doi: 10.3390/cancers12071766.

Endocrine Risk Factors of Endometrial Cancer: Polycystic Ovary Syndrome, Oral Contraceptives, Infertility, Tamoxifen

Atanas Ignatov  1 , Olaf Ortmann  1
Affiliations
Review

Endocrine Risk Factors of Endometrial Cancer: Polycystic Ovary Syndrome, Oral Contraceptives, Infertility, Tamoxifen

Atanas Ignatov et al. Cancers (Basel). .

Abstract

Endometrial cancer is the most common gynecologic cancer and is predominantly endocrine-related. The role of unopposed estrogen in the development of endometrial cancer has been investigated in numerous studies. Different reproductive factors such as younger age at menarche, late age at menopause, infertility, nulliparity, age of birth of the first child, and long-term use of unopposed estrogens during hormone replacement therapy have been associated with an increased risk of endometrial cancer. In contrast, there is a growing body of evidence for a protective role of oral contraceptives. Most of the published data on the association between infertility and polycystic ovary syndrome are inconclusive, whereas the effect of tamoxifen on the risk of endometrial cancer has been well established. With this review, we aim to summarize the evidence on the association between infertility, polycystic ovary syndrome, oral contraceptives, and tamoxifen and the development of endometrial cancer.

Keywords: PCOS; endometrial cancer; infertility; oral contraceptives; tamoxifen.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

References

    1. Colombo N., Creutzberg C., Amant F., Bosse T., Gonzalez-Martin A., Ledermann J., Marth C., Nout R., Querleu D., Mirza M.R., et al. Esmo-esgo-estro consensus conference on endometrial cancer: Diagnosis, treatment and follow-up. Ann. Oncol. 2016;27:16–41. doi: 10.1093/annonc/mdv484. - DOI - PMC - PubMed
    1. Ali A.T. Reproductive factors and the risk of endometrial cancer. Int. J. Gynecol. Cancer. 2014;24:384–393. doi: 10.1097/IGC.0000000000000075. - DOI - PubMed
    1. Yang H.P., Cook L.S., Weiderpass E., Adami H.O., Anderson K.E., Cai H., Cerhan J.R., Clendenen T.V., Felix A.S., Friedenreich C.M., et al. Infertility and incident endometrial cancer risk: A pooled analysis from the epidemiology of endometrial cancer consortium (e2c2) Br. J. Cancer. 2015;112:925–933. doi: 10.1038/bjc.2015.24. - DOI - PMC - PubMed
    1. Skalkidou A., Sergentanis T.N., Gialamas S.P., Georgakis M.K., Psaltopoulou T., Trivella M., Siristatidis C.S., Evangelou E., Petridou E. Risk of endometrial cancer in women treated with ovary-stimulating drugs for subfertility. Cochrane Database Syst. Rev. 2017;3:CD010931. doi: 10.1002/14651858.CD010931.pub2. - DOI - PMC - PubMed
    1. Reigstad M.M., Storeng R., Myklebust T.A., Oldereid N.B., Omland A.K., Robsahm T.E., Brinton L.A., Vangen S., Furu K., Larsen I.K. Cancer risk in women treated with fertility drugs according to parity status-a registry-based cohort study. Cancer Epidemiol. Biomarkers Prev. 2017;26:953–962. doi: 10.1158/1055-9965.EPI-16-0809. - DOI - PMC - PubMed

LinkOut - more resources